Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 6

Effects of treatment with antimicrobial agents on the human colonic microflora

Authors Rafii F, Sutherland JB, Cerniglia CE

Published 5 December 2008 Volume 2008:4(6) Pages 1343—1357


Review by Single-blind

Peer reviewer comments 6

Fatemeh Rafii, John B Sutherland, Carl E Cerniglia

Division of Microbiology, National Center for Toxicological Research, FDA, Jefferson, AR, USA

Abstract: Antimicrobial agents are the most valuable means available for treating bacterial infections. However, the administration of therapeutic doses of antimicrobial agents to patients is a leading cause of disturbance of the normal gastrointestinal microflora. This disturbance results in diminishing the natural defense mechanisms provided by the colonic microbial ecosystem, making the host vulnerable to infection by commensal microorganisms or nosocomial pathogens. In this minireview, the impacts of antimicrobials, individually and in combinations, on the human colonic microflora are discussed.

Keywords: antibiotics, intestinal bacteria

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Below and beyond the recognition of emotional facial expressions in alcohol dependence: from basic perception to social cognition

D’Hondt F, Campanella S, Kornreich C, Philippot P, Maurage P

Neuropsychiatric Disease and Treatment 2014, 10:2177-2182

Published Date: 18 November 2014

A comparison of three multidimensional indices of COPD severity as predictors of future exacerbations

Motegi T, Jones RC, Ishii T, Hattori K, Kusunoki Y, Furutate R, Yamada K, Gemma A, Kida K

International Journal of Chronic Obstructive Pulmonary Disease 2013, 8:259-271

Published Date: 31 May 2013

Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses

Hideki Hasegawa, Takeshi Ichinohe, Akira Ainai, Shin-ichi Tamura, Takeshi Kurata

Therapeutics and Clinical Risk Management 2009, 5:125-132

Published Date: 9 March 2009

Frequency and clinical relevance of human bocavirus infection in acute exacerbations of chronic obstructive pulmonary disease

Felix C Ringshausen, Ai-Yui M Tan, Tobias Allander, Irmgard Borg, Umut Arinir, et al

International Journal of Chronic Obstructive Pulmonary Disease 2009, 4:111-117

Published Date: 4 February 2009

Correlation of microalbumin and sialic acid with anthropometric variables in type 2 diabetic patients with and without nephropathy

B Shivananda Nayak, Heidi Duncan, Sunita Lalloo, Kevin Maraj, Vani Matmungal, et al

Vascular Health and Risk Management 2008, 4:243-247

Published Date: 8 February 2008

Prulifloxacin: a brief review of its potential in the treatment of acute exacerbation of chronic bronchitis

Francesco Blasi, Stefano Aliberti, Paolo Tarsia, PierAchille Santus, Stefano Centanni, Luigi Allegra

International Journal of Chronic Obstructive Pulmonary Disease 2007, 2:27-31

Published Date: 15 April 2007

Renal cell carcinoma and the use of sorafenib

James MG Larkin, Tim Eisen

Therapeutics and Clinical Risk Management 2006, 2:87-98

Published Date: 15 March 2006